On Mar. 10, 2022, Oragenics announced that it had entered into an agreement with KBI Biopharma for the process transfer, process optimization and cGMP manufacturing of the Companyﾒs intranasal vaccine candidate NT-CoV2-1, which is expressed in a proprietary CHO cell line.

The agreement covered, among other things, both a 200L demonstration run and a 500L cGMP run.